Cefpirome is a fourth-generation cephalosporin with good in-vitro activity against both Grampositive and Gram-negative aerobes, including Pseudomonas spp. A multicentre, randomized trial was performed to compare cefpirome at a dose of 2 g bd iv with ceftazidime (2 g tds iv) in the empirical treatment of suspected bacteraemia in patients with severe sepsis but not septic shock. The majority of the patients had community-acquired infections. Patients were stratified into high-and low-risk groups using a Simplified Sepsis Score. Metronidazole, an aminoglycoside or a glycopeptide could be added to the treatment as required. In patients with a positive blood culture treated for 48 h, the clinical success rates were 37/48 (77%) for cefpirome and 35/52 (67%) for ceftazidime with no significant difference between the two. In patients with bacteriologically proven infection, 92 (89%) of 103 patients treated with cefpirome were assessed as cured and 94 (89%) of 106 patients with treated ceftazidime. More Gram-positive pathogens, enterococci and staphylococci were resistant in vitro to ceftazidime than to cefpirome (15/90 (17%) and 5/92 (5%) respectively; 2 = 4.8, P < 0.05) but the bacteriological response was not significantly different between the two groups (cefpirome, 54/60 (90%); ceftazidime, 54/63 (86%)). Cefpirome showed equivalent efficacy and safety to ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Regarding safety, there were no statistically significant differences between the two treatments, with adverse events thought to be possibly related to the study drug occurring in 55/187 and 40/184 patients on cefpirome and ceftazidime, respectively. †Study Group:
Introduction
Cefpirome is a fourth-generation cephalosporin. In comparison with second-, third-and other fourth-generation derivatives it has higher activity against Gram-positive pathogens, good activity against Pseudomonas aeruginosa and a markedly improved stability to the chromosomal Class I cephalosporinase commonly produced by Enterobacter spp. [1] [2] [3] [4] Cefpirome has a high degree of safety and the risk of nephrotoxicity is low. 5 It has been shown to be effective in the treatment of bacteraemia in a number of trials, including nine which were comparative. 6 The combination of broad spectrum and low toxicity suggests that cefpirome would be useful for treating patients with severe sepsis and might show a clinical benefit over ceftazidime because of its antistaphylococcal activity.
The present open, controlled, multicentre, centrally randomized trial was performed to compare the safety and efficacy of cefpirome with ceftazidime in the critically ill patient. The APACHE III score is used in these patients to measure severity of illness and has the potential to predict outcome. 7 For the purposes of this study, a Simplified Sepsis Score (SSS) was used to divide patients into high-and low-risk strata by a threshold score of 30. It was based on easily obtainable information about the patients entered, and its relationship to outcome was compared with that of the full APACHE III score. 
Materials and methods
The study was a multicentre, randomized trial of hospitalized patients with suspected bacteraemia comparing cefpirome (2 g bd iv) and ceftazidime (2 g tds iv). Good Clinical Practice guidelines were followed and approval was obtained from the Ethics Committees of participating hospitals. Informed consent was required from all patients or their relatives.
Patients were recruited if they were aged over 18 years, had clinical evidence of infection requiring a broadspectrum antibiotic and two or more of the following: temperature 38°C or 36°C, heart rate 90 beats/min, respiratory rate 20 breaths/min or pCO 2 4.2 kPa, and WBC 12,000/mm 3 or 4000/mm 3 or 10% band forms. 9 Exclusion criteria were: hypersensitivity to penicillins or cephalosporins, 24 h treatment with an antibiotic (or any treatment with the study drugs) for this infection, pregnancy, lactation, burns, AIDS, neutropenia ( 1000 neutrophils/mm 3 ), meningitis, endocarditis, septic shock, life expectancy 5 days or severe chronic renal failure ( 5 mL/min). Patients were withdrawn at their or the investigator's request if treatment failed and other antibiotics were used, if there was bacteriological failure resulting from a resistant pathogen in the blood, a persistent pathogen or a superinfection, or if there were serious adverse events. If two consecutive doses or more than two doses at other times were missed, the patient was excluded from assessment of efficacy. The patients were stratified into four groups according to risk factors by the Simplified Sepsis Score (SSS). It was recommended that treatment with the study drugs was continued 2 days after defervescence. A significantly higher rate of death in one group was to be taken as an indication that the study should be stopped.
Patients with acute renal failure were given reduced doses of cefpirome depending on their creatinine clearance as follows: 20-50 mL/min, 2 g then 1 g bd; 5-20 mL/ min, 2 g then 1 g od; 5 mL/min, 2 g then 1 g od plus 0.5 g after dialysis. The number of doses of ceftazidime was also reduced: creatinine clearance 31-50 mL/min, 2 g then 1 g tds; 16-30 mL/min, 2 g then 0.5 g tds; 6-15 mL/min, 2 g then 0.5 g bd; 5 mL/min, 2 g then 0.5 g od plus 0.5 g after dialysis. Patients were randomized using a central system of a voice-output computer over the telephone. Patients who were withdrawn were not replaced.
Patients with proven or suspected intra-abdominal or pelvic infection were given metronidazole in addition to the study drug. Patients thought to have pseudomonal infection were concomitantly treated with aminoglycoside and those suspected of having enterococcal infection or methicillin-resistant Staphylococcus aureus infection were given vancomycin. Dosages and choice of aminoglycoside as well as dosages of vancomycin were those recommended by the manufacturer. Most patients with normal function who received aminoglycosides were given these antibiotics two or three times daily. The concomitant antibiotic(s) could be stopped if a pathogen was found to be susceptible to the study drug. Antiviral or antifungal agents could be used. If the responsible pathogen was found to be resistant to the study drug, an appropriate antibiotic could be added unless there was clear clinical improvement (but classified as a bacteriological failure). If there were continuing clinical signs of infection and fever ( 37.9°C) but no identified pathogen, an antibiotic could be added after 48 h (clinical treatment failure). A change to a different antibiotic constituted withdrawal.
Clinical response was assessed 1-5 days after the end of treatment in patients with bacteriologically proven sepsis not withdrawn following protocol violation or other reasons. Follow-up examinations were made 10-30 days after the end of treatment. Cure was defined as a satisfactory or improved clinical outcome without additional antibiotic treatment. Bacteriological response was determined by cultures before (within 48 h before start) and after treatment and susceptibility testing of the probable pathogen. Follow-up cultures were taken at 72 h after the start of treatment, before any antibiotic changes, within 48 h of completion and before any subsequent antibiotic treatment. Blood cultures were repeated if fever persisted for 48 h. A satisfactory bacteriological outcome was defined as absence of the pathogen on post-treatment culture (eradication). A pathogen was considered persistent if isolated during treatment. Relapse was defined as reappearance of the pathogen in later cultures. Superinfection was defined as infection at any site by another pathogen requiring concomitant treatment during the study period and reinfection was defined as infection requiring treatment after the end of study-drug treatment. Outcomes were assessed by strict protocol criteria (computer based), the investigator (14 days after the treatment had finished) and by an external expert blinded to treatment assignment.
Adverse events were elicited by the investigator or reported by the patient, by observation of clinical signs and by haematological or biochemical tests. Laboratory variables were determined 24 h before entry, then every 4-7 days during treatment and within 48 h after completion of treatment. Deaths during inpatient stay or within 14 days of the end of treatment were analysed.
Antibiotic susceptibility testing was carried out by standard NCCLS methods.
10 MIC breakpoints for cefpirome were as follows: 8 mg/L, susceptible; 32 mg/L, resistant. Those for ceftazidime were: 8 mg/L, susceptible; 64 mg/L, resistant. MICs were determined in a central laboratory.
Simplified Sepsis Score
The SSS was derived by adding points gained on six physiological variables (heart rate, blood pressure, temperature, respiratory rate, Glasgow Coma Score, white blood cell count) plus points for age, the most unfavourable value in the preceding 24 h being taken. Patients entering the trial were split first by the need for combination or monotherapy and then by SSS above or below 30 before balanced 1:1 randomization into antibiotic groups. The Pearson correlation coefficient of SSS and APACHE III was calculated to show the validity of SSS.
Statistical methods
Clinical response was assumed to be 80% for both antibiotic groups with a maximum difference of 15% between them to be considered equivalent treatments. Given a type I two-sided error of 0.05 and a type II error of 0.2, a total of 360 patients would be needed if only 50% patients recruited were evaluable (symptomatic patients who received the study drug for at least 48 h without protocol violation or withdrawal). Efficacy analyses were performed on the following groups: all patients randomized (intention-to-treat analysis); patients with symptoms according to protocol, no major protocol violations and treatment with study drugs for 48 h; patients who also had bacteriologically verified sources of infection; patients who also had verified bacteraemia.
Mortality rates were compared by the 2 test. Logistic regression was performed to establish the risk factors for death. A data safety review committee monitored safety and could stop the trial if mortality in one arm was higher. A stopping rule for mortality was designed to give a 95% probability of detecting a difference between 17.5% and 32% mortality respectively, in the two arms with a significance of 5%. 11 Changes in the medians of laboratory parameters were tested by Friedman tests with multiple comparisons according to Nemenyi.
Results
Twenty-eight centres in Germany, Finland, Sweden, Belgium, Italy and Spain recruited 376 patients between April 1993 and March 1995. In total, 188 patients were enrolled in each treatment group. Only two patients in each group were non-Caucasian. Protocol violations occurred in 26 (7%) of 376 patients, four being assigned to the wrong stratum (Table I) . Five patients were given the wrong antibiotic and five did not receive any. From each group 32 patients were withdrawn because of treatment failure or death and a total of 13 (eight receiving cefpirome and five ceftazidime) were withdrawn after adverse events (Table I ).
An evaluable response without major protocol violation was observed in 333 patients, 164 in the cefpirome group and 169 in the ceftazidime group. In each group, 110 patients had a positive culture before treatment. Positive blood cultures were recorded in 48 and 52 patients, respectively. APACHE III scores and SSSs were similar, with 51 (27%) in the cefpirome group and 47 (24%) in the ceftazidime group having SSSs of 30. The APACHE III score and the SSS were correlated (correlation coefficient 0.78).
At inclusion, respiratory tract infection was present in 148/376 (39%) patients. There was no significant difference between the demographic features of the two groups (Table II) . Underlying disease was usually cardiovascular (143 patients, 38%), genitourinary (126 patients, 34%) or respiratory (94 patients, 25%) without significant differences between the groups. Most patients had communityacquired infection (294, 78%) and 141 (38%) had renal failure (creatinine clearance 50 mL/min). Pneumonia was the most common diagnosis on entry, being diagnosed in 163 patients, of whom 150 (92%) were confirmed radiologically (Table III) . Assisted ventilation was required in more patients given cefpirome (39, 21%) than in those given ceftazidime (29, 15%) (difference not significant). There were no significant differences between entry diagnoses. In the 5 days before entry, 66/188 (35%) patients in the cefpirome group and 75/188 (40%) patients in the ceftazidime group received other antibiotics, usually penicillins or cefuroxime. Monotherapy was given to 155 (82%) patients in the cefpirome group and 146 (78%) patients in the ceftazidime group. Others were given additional metronidazole (43 patients) or vancomycin (35 patients). Monotherapy was sufficient for the whole course of treatment in 117 (62%) of the cefpirome group and 119 (63%) of the ceftazidime group. Antibiotics were added to the treatment of 13 patients in each group and were changed in 24 (13%) and 17 (9%) respectively. Antifungal agents were given to 25 patients in the cefpirome group and 19 in the ceftazidime group.
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The most common concomitant antimicrobials given to patients who had sepsis symptoms and who were treated for 48 h or more were systemic antifungals (cefpirome, 18/110; ceftazidime, 13/110) and antiseptic/antifungal mouthwashes (cefpirome, 8/110; ceftazidime, 5/110). Antivirals were given to one patient on ceftazidime, and selective gut decontamination to two patients on cefpirome. Additional antibacterial agents were given in 22 patients in the cefpirome group and 16 in the ceftazidime group. Twelve patients in each group received one additional antibacterial, eight patients on cefpirome and four on ceftazidime received two additional agents, and two patients in the cefpirome group received three additional agents. The most frequently used antibacterials were co-amoxiclav (given to four patients in the cefpirome group and ten in the ceftazidime group), cephalexin (given to three in the cefpirome group and one in the ceftazidime group), netilmicin (given to three in the cefpirome group and one in the ceftazidime group), metronidazole (given to three in the cefpirome group), and clindamycin, ciprofloxacin or co-trimoxazole (each given to two patients in the cefpirome arm).
Outcome was similar in the two groups whichever population was analysed (Table IV) . Treatment was for a median of 9 days in both groups (cefpirome range, 1-23 days; ceftazidime range, 0-25 days). The investigator's assessment of outcome based on bacteriologically proven infection was 92/103 (89%) cured on cefpirome and 94/106 (89%) cured on ceftazidime. The difference (0.6%) was not statistically significant (90% CI, -6.5, 7.8). At 10-30 days after treatment, clinical success was achieved in 71% of the cefpirome group and 74% of the ceftazidime group, respectively. Similar results were obtained using a blinded evaluator (87/101 vs 86/103; difference, 2.6%; 90% CI, -5.6, 10.9). Patients given monotherapy had higher cure rates than those requiring combination treatment (intentto-treat analysis: monotherapy, 107/155 (69%) vs 113/151 More Gram-positive pathogens, enterococci and staphylococci, were resistant to ceftazidime than to cefpirome (ceftazidime, 15/90 (17%); cefpirome, 5/92 (5%); 2 4.8, P 0.05). However, the bacteriological response was not significantly different between the two groups (cefpirome, 54/60 (90%); ceftazidime, 54/63 (86%)). Of 52 cefpirome patients with a positive blood culture, 37 (77%) were cured compared with 37 (67%) of 55 ceftazidime patients. One superinfection in the cefpirome group and one reinfection in the ceftazidime group were recorded.
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For respiratory infection, the cure rates were similar for the two groups (cefpirome, 46/80 (58%); ceftazidime, 54/83 (65%)). To a large extent the relatively low cure rates in these patients resulted from remaining pulmonary infiltrates at the end of therapy. There was also no significant difference in the cure rates of pyelonephritis and urinary infection (54/67 (81%); 51/62 (82%) for cefpirome and ceftazidime, respectively).
At follow-up (10-30 days) by intent-to-treat analysis, 79 (62%) of 127 patients receiving cefpirome had been cured and 83 (67%) of 124 patients receiving ceftazidime. Nine patients in the cefpirome group and 13 in the ceftazidime group failed during the follow-up period after apparent cure at the end of treatment. Four of the cefpirome patients and two of the ceftazidime patients were found to have a new bacterial isolate in the urine.
All 371 patients given at least one dose of medication were analysed for safety. Adverse events were observed in 111/187 (59%) of patients given cefpirome and 85/184 (46%) given ceftazidime (Table V) . Events possibly related to the study drug occurred in 55 (29%) of 187 patients given cefpirome and 40 (22%) of 184 patients given ceftazidime. No significant differences between the groups were detected. The most common events were abnormalities in liver or renal function and diarrhoea. Serious adverse events occurred in 40 patients in each group; there were no significant differences in cause between the groups. In the cefpirome group, 19 (10%) patients experienced general effects (e.g. fever, sepsis or multiple organ failure) and 19 (10%) reported respiratory, 17 (9.1%) cardiovascular, eight (4.3%) urogenital, five (2.7%) nervous and five (2.7%) digestive adverse events. In the ceftazidime group, general effects were recorded in 23 (12%), respiratory effects in 17 (9.2%), cardiovascular effects in 18 (9.5%), urogenital effects in 8 (4.3%), nervous effects in nine (4.9%) and digestive effects in six (3.2%). A similar proportion of patients was withdrawn from the two groups following adverse events (cefpirome 13/187 (7%); ceftazidime, 12/184 (7%)).
Clostridium difficile was not isolated from any patient in the study reporting diarrhoea as an adverse event. No superinfections with C. difficile were reported.
Fifteen patients in the cefpirome group and 23 in the ceftazidime group died within 14 days of treatment; deaths were usually related to sepsis or organ failure. None of the causes of death was thought by the investigators to be causally related to the study drug. Haematological and biochemical parameters were not significantly different between the two groups at baseline or endpoint. Although improvements were found with treatment, no changes suggestive of toxicity were found by the Friedman test. Mortality was significantly higher for ceftazidime, but not for cefpirome, in patients with an initial SSS of 30 points (nine deaths (7%) among the 135 patients in the cefpirome group with an SSS of 30, compared with six deaths (12%) among the 52 patients in the cefpirome group with an SSS of 30; P NS; of the patients receiving ceftazidime, ten (7%) of the 139 with an SSS of 30 died, compared with 13/45 (29%) of those with an SSS of 30; P 0.05). Using a forward stepwise logistic regression to predict mortality, the APACHE III score was highly significant (P 0.0001), followed by the use of combination therapy (P 0.0005) but treatment choice was not significant (P 0.17). The SSS could be substituted for the APACHE III score in the regression equation. The APACHE III score and the SSS were both predictive for risk of death.
Discussion
Cefpirome was as effective as ceftazidime in the treatment of patients with suspected bacteraemia or sepsis. The failure rates in both treatment groups were typical for seriously ill patients and were predictably higher in those patients thought to need combination therapy. Cefpirome was more active against the Gram-positive pathogens isolated than ceftazidime, but bacteriological efficacy was not significantly different between the two groups. Adverse events in each group were those expected in seriously ill patients and were again similar for each cephalosporin.
Early effective treatment is essential in the bacteraemic patient. Treatment has to be broad spectrum because fewer than half of cases are proven by blood culture. The incidence of bacteraemia is increasing as more patients survive more aggressive treatment and invasive monitoring. The Enterobacteriacae, staphylococci, pneumococci and pseudomonas are the common isolates from blood cultures but there is a clear rise in the proportion of cases caused by staphylococci. 12 Ceftazidime is frequently used for empirical treatment, particularly for nosocomial infections, but, despite its anti-pseudomonal action, activity against staphylococci is poor. Cefpirome had better activity than ceftazidime against Gram-positive bacteria in this trial and the low proportion of resistant pathogens was similar to those found in larger surveys of clinical isolates. 13 The clinical efficacy of cefpirome was similar to that of ceftazidime in this trial. However, cefpirome showed invitro advantages over ceftazidime with respect to its activitity against Gram-positive pathogens. The clinical relevance of that improved in-vitro activity remains to be demonstrated. Other studies confirm the similarity in response to cefpirome and ceftazidime in septicaemia, although the rates of cure or improvement differ according to the patient population. A review of 15 clinical trials identified 176 patients with confirmed septicaemia treated with cefpirome and 50 treated with ceftazidime. 6 Of 177 patients given cefpirome, 131 (74%) were cured and 39 (22%) were improved compared with 34 (68%) and 11 (22%) of 50 treated with ceftazidime. Bacteriological cure was achieved in 123 (89%) of 138 patients and 27 (90%) of 30 patients respectively. In patients in the intensive care unit, patients with serious nosocomial infections had the same cure rate (82%) whether cefpirome (37/45) or ceftazidime (40/49) was used.
14 Cefpirome might still be preferred over ceftazidime because it is administered twice rather than three times a day and has a prolonged post-antibiotic effect against Gram-positive bacteria. 15 The half-life of cefpirome increases with falling renal function and dosage interval has to be increased. Cefpirome is removed by haemodialysis in complete renal failure (40% in 4 h). 16 Adverse effects following cefpirome are similar to those following other cephalosporins. In a review of randomized trials, including a total of 3103 patients treated with cefpirome, adverse events were reported in 679 (22%), 387 (13%) of which were possibly related to the drug. 5 The most frequent effects were cardiovascular or gastrointestinal in nature. Ceftazidime was given to 1134 patients, of whom 297 (26%) experienced adverse events, 140 (12%) possibly related to the antibiotic. Cefpirome was discontinued in 159 (5%) patients, the same proportion of patients who were withdrawn from treatment with ceftazidime (57/1134, 5%). Mortality rate in patients given cefpirome or ceftazidime was similar in other trials, both to the results in this trial and to each other. In 378 patients with septicaemia, 28/282 (9.9%) died on cefpirome compared with 10/80 (12.5%) on ceftazidime. SSS was validated for use in predicting mortality in this patient group. Scoring systems, such as APACHE III, applied to patients who did and did not meet sepsis syndrome criteria produce overlapping mortality risks in both groups. 17 Although the APACHE III system is widely used to describe patients with sepsis, it is not designed to monitor infection alone. Changes in the weightings used for some risk factors have been proposed which improve the predictive power of APACHE in sepsis. 8 In this study, the SSS, which used readily-obtained patient information, behaved similarly to APACHE III when used in logistic regression to predict mortality. Therefore SSS might be suitable for trials of treatment of sepsis syndrome in the critically ill.
Cefpirome is an effective and safe choice for the empirical treatment of bacteraemia. Its broader antibacterial spectrum compared with ceftazidime supports its use in severe infections because of the increasing importance of infections due to Gram-positive pathogens. Its twice-daily dosage regimen can also provide savings in the hospital setting, both in terms of time for patient care and drug costs.
